Santhera plan to repay its debt of CHF 29m ($33.8m) to Highbridge Capital and fund the pre-commercialization and launch of vamorolone in Europe. Image Credit: TRADOL / Shutterstock.

Santhera Pharmaceuticals has signed an exclusive licensing agreement with Catalyst Pharmaceuticals for the North American commercialisation of vamorolone, an investigational therapy for Duchenne muscular dystrophy (DMD).

Santhera has developed vamorolone in collaboration with ReveraGen BioPharma. The drug is currently an approval decision with a US Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) review date set for 26 October 2023. Vamorolone has an Orphan Drug status in the US and EU, along with a Promising Innovative Medicine (PIM) status in the UK for treating DMD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Vamorolone acts by binding to glucocorticoid receptors, thereby, modifying disease activity while reducing the adverse effects from the standard steroid therapy.

The agreement with Catalyst is worth up to $231m plus sales royalties for Santhera. Of these, $75m will be an upfront cash payment, with $15m in treasury shares sale to Catalyst. Additional milestone-based payments include $26m for Santhera’s third-party regulatory and royalty obligations and $105m in sales-based milestones.

Santhera plan to repay its debt of SFr29m ($33.8m) to Highbridge Capital and fund the pre-commercialisation and launch of vamorolone in Europe. The first European launch is expected later this year in Germany.

See Also:

Santhera plans to launch the drug in the five largest European countries plus Benelux, the economic region of Belgium, the Netherlands, and Luxembourg, by itself, and is looking for partnerships in other regions, except US and China where it has existing partnerships.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In June 2023, the FDA granted accelerated approval for the first-ever gene therapy for DMD, Elevidys (delandistrogene moxeparvovec-rokl) by Sarepta Therapeutics.

Vamorolone is also under investigation for Becker muscular dystrophy in a US FDA-funded Phase II pilot study (NCT05166109).

Other drugs in the Santhera pipeline include lonodelestat, which was leased from Polyphor AG for development and commercialisation in cystic fibrosis (CF), alpha-1 antitrypsin deficiency (AADT), primary ciliary dyskinesia (PCD), and other lung diseases. It is currently under regulatory review with orphan drug status in the US and EU for CF, AADT, and PCD.